Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InDEX: Individualized MDR-TB Treatment Strategy
NCT03237182Phase 4Terminated
- Sponsor
- CAPRISA
- Start
- Jun 2017
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Tuberculosis (TB) (2 arms), sponsored by CAPRISA. Primary endpoint: Culture negative survival rate at 24 months. Started Jun 2017; status: terminated.
02
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03237182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237182.